Andrea Gombos

TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.

TL;DR: This single-arm, multicentre, phase 1b-2 trial assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastzumab-resistant, advanced HER2-positive breast cancer.

TL;DR: The combination of immune checkpoint blockade with conventional cancer treatments such as chemotherapy, radiotherapy, targeted therapies or with other immunotherapies is a promising strategy to potentiate its efficacy in breast cancer although further research is required to effectively identify who will respond to these immunotheraps.

TL;DR: Extended intermittent use of adjuvant letrozole in postmenopausal women with hormone receptor-positive, lymph node- positive, and operable breast cancer for which they had undergone local treatment and had completed 4-6 years of adjUvant endocrine therapy is hypothesised to improve breast cancer outcome compared with continuous use of letroZole.

TL;DR: The higher ORR and Ki67 reduction in the ER+, HER2+ subgroup indicates a potential role for PI3K-targeted therapy in this setting and may warrant further investigation with better-tolerated second-generation PI3k inhibitors.